NASDAQ: ADAG
Adagene Inc Stock Forecast, Predictions & Price Target

Analyst price target for ADAG

Based on 4 analysts offering 12 month price targets for Adagene Inc

Min Forecast
$7.00+251.76%
Avg Forecast
$8.00+302.01%
Max Forecast
$9.00+352.26%

Should I buy or sell ADAG stock?

Based on 4 analysts offering ratings for Adagene Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ADAG stock forecasts and price targets.

ADAG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-24
lockedlocked$00.00+00.00%2025-09-18
lockedlocked$00.00+00.00%2025-08-15
lockedlocked$00.00+00.00%2025-08-06

1 of 1

Forecast return on equity

Is ADAG forecast to generate an efficient return?

Company
N/A
Industry
259.27%
Market
228.52%

Forecast return on assets

Is ADAG forecast to generate an efficient return on assets?

Company
N/A
Industry
90.14%

ADAG earnings per share forecast

What is ADAG's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.55
Avg 2 year Forecast
-$0.74
Avg 3 year Forecast
-$0.56

ADAG revenue forecast

What is ADAG's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$7.3M+6,983.06%
Avg 2 year Forecast
$9.9M+9,536.25%
Avg 3 year Forecast
$6.9M+6,593.54%
ADAG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADAG revenue growth forecast

How is ADAG forecast to perform vs Biotechnology companies and vs the US market?

Company
326.44%
Industry
102.02%
Market
25.67%
ADAG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADAG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADAG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADAG$1.99$8.00+302.01%Strong Buy
ADVM$4.26$13.50+216.90%Buy
ELDN$1.58$8.50+437.97%Strong Buy
ANEB$2.26N/AN/A
RPTX$2.22$3.00+35.44%Buy

Adagene Stock Forecast FAQ

Is Adagene Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ADAG) stock is to Strong Buy ADAG stock.

Out of 4 analysts, 2 (50%) are recommending ADAG as a Strong Buy, 2 (50%) are recommending ADAG as a Buy, 0 (0%) are recommending ADAG as a Hold, 0 (0%) are recommending ADAG as a Sell, and 0 (0%) are recommending ADAG as a Strong Sell.

If you're new to stock investing, here's how to buy Adagene stock.

What is ADAG's earnings growth forecast for 2025-2027?

(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Adagene's earnings in 2025 is -$29,889,635.On average, 9 Wall Street analysts forecast ADAG's earnings for 2025 to be -$32,691,427, with the lowest ADAG earnings forecast at -$37,528,273, and the highest ADAG earnings forecast at -$27,836,906. On average, 9 Wall Street analysts forecast ADAG's earnings for 2026 to be -$43,625,881, with the lowest ADAG earnings forecast at -$69,282,966, and the highest ADAG earnings forecast at -$24,125,319.

In 2027, ADAG is forecast to generate -$33,251,111 in earnings, with the lowest earnings forecast at -$44,456,570 and the highest earnings forecast at -$27,218,308.

What is ADAG's revenue growth forecast for 2025-2027?

(NASDAQ: ADAG) Adagene's forecast annual revenue growth rate of 326.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Adagene's revenue in 2025 is $103,204.On average, 8 Wall Street analysts forecast ADAG's revenue for 2025 to be $430,661,976, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,237,195,827. On average, 7 Wall Street analysts forecast ADAG's revenue for 2026 to be $585,900,595, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,299,055,618.

In 2027, ADAG is forecast to generate $406,978,513 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,113,476,244.

What is ADAG's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ADAG) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 90.14%.

What is ADAG's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ADAG price target, the average ADAG price target is $8.00, with the highest ADAG stock price forecast at $9.00 and the lowest ADAG stock price forecast at $7.00.

On average, Wall Street analysts predict that Adagene's share price could reach $8.00 by Nov 24, 2026. The average Adagene stock price prediction forecasts a potential upside of 302.01% from the current ADAG share price of $1.99.

What is ADAG's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ADAG) Adagene's current Earnings Per Share (EPS) is -$0.64. On average, analysts forecast that ADAG's EPS will be -$0.55 for 2025, with the lowest EPS forecast at -$0.64, and the highest EPS forecast at -$0.47. On average, analysts forecast that ADAG's EPS will be -$0.74 for 2026, with the lowest EPS forecast at -$1.18, and the highest EPS forecast at -$0.41. In 2027, ADAG's EPS is forecast to hit -$0.56 (min: -$0.75, max: -$0.46).

What is ADAG's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ADAG) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.